drugset / Trial / NCT03190733

A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT

NCT03190733 ↗

RandomizedParallel-groupSingle-blindPrevention

Summary

In this study, a randomized, prospective, multicenter, open cohort study was conducted to investigate patients with acute leukemia (14~60-year-old) with different ATG doses (10 mg / kg and 12.5 mg / kg ) in fludarabine, busulfan, cyclophosphamide and antilymphocyte globulin (FBCA) pretreatment protocol of Haploidentical hematopoietic stem cell transplantation (haplo-HSCT). The purpose is to compare the incidences of chronic graft vs host disease (cGVHD) in haplo-HSCT recipients receiving different dose ATG and one year leukemia relapse after transplantation. The main objective was to investigate the optimal dose of ATG for decrease cGVHD and not increase one year relapse leukemia after haplo-HSCT. Its significance is to provide evidence-based medical evidence to reduce the occurrence of cGVHD and to improve the quality of life of patients with haplo-HSCT.

Timeline

Start
2017-08-30
Primary completion
2020-09-30
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ATG Protein / enzyme biologic 10 mg/kg Intravenous
Subject ATG Protein / enzyme biologic 12.5 mg/kg Intravenous